Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Drug Discovery: Overview

Drug Discovery: Overview

Drug discovery is a multifaceted process involving extensive screening, testing, and optimization of lead compounds to identify potential new drugs for therapeutic use. It combines several approaches, including screening large numbers of natural products, chemical modification of known active molecules, identification of new drug targets, and rational design based on biological mechanisms and drug-receptor structure. These approaches are carried out in both academic research laboratories and...

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...

Pharmacogenomics: Identification of New Drug Targets

Pharmacogenomics: Identification of New Drug Targets

Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...

Agonism and Antagonism: Quantification

Agonism and Antagonism: Quantification

When drugs are administered, they can elicit either an agonist or antagonist effect on the body. Agonism occurs when a drug activates a specific receptor, triggering a biological response. On the other hand, antagonism happens when a drug binds to the same receptors but blocks their activation, thereby preventing a biological response.
To quantify these effects, researchers use a dose-response curve, which provides valuable information about the potency and efficacy of a drug. Potency refers to...

Combined Effects of Drugs: Synergism

Combined Effects of Drugs: Synergism

Synergism is a useful mechanism where combining two or more drugs is more effective than each constituent used alone. Such combinations are also called supra-additive interactions. The drugs collectively enhance the final therapeutic effect by acting on different targets. Another advantage is that the low dose of each constituent drug is sufficient to achieve the desired effect. This helps reduce the duration of therapy and lower the adverse effects of these drugs.
Such synergistic combinations...

Pharmacogenetics and Pharmacogenomics: Overview

Pharmacogenetics and Pharmacogenomics: Overview

Pharmacogenetics and pharmacogenomics examine how genetic factors influence an individual's response to drugs. While pharmacogenetics focuses on the impact of specific genetic variants on drug effects, pharmacogenomics takes a broader approach, studying how genetic variation across populations contributes to differences in drug responses. These fields aim to explain why individuals may experience varying levels of efficacy or adverse reactions to the same medication.Variability in drug...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Web-Based User Interface for Fam3PRO: A Multigene, Multicancer Risk Prediction Model for Families With Cancer History.

JCO clinical cancer informatics·2026

Same author

Correction: Shared genetics between breast cancer and predisposing diseases identifies novel breast cancer treatment candidates.

Human genomics·2025

Same author

Shared genetics between breast cancer and predisposing diseases identifies novel breast cancer treatment candidates.

Human genomics·2024

Same author

Shared etiology of Mendelian and complex disease supports drug discovery.

BMC medical genomics·2024

Same author

Enhanced machine learning approaches for OSA patient screening: model development and validation study.

Scientific reports·2024

Same author

Shared genetics between breast cancer and predisposing diseases identifies novel breast cancer treatment candidates.

Research square·2024

Search research articles

Related Experiment Video

Updated: Jun 20, 2026

A Knowledge Graph Approach to Elucidate the Role of Organellar Pathways in Disease via Biomedical Reports

A Knowledge Graph Approach to Elucidate the Role of Organellar Pathways in Disease via Biomedical Reports

Published on: October 13, 2023

A Knowledge Graph Approach To Discovering Drug Combination Therapies Across The Phenome.

Jianfeng Ke^1,2, Tingjian Ge¹, Rachel D Melamed²

¹Department of Computer Science, University of Massachusetts Lowell, Lowell, MA, USA.

AMIA Joint Summits on Translational Science Proceedings. AMIA Joint Summits on Translational Science

|June 19, 2026

Summary

Discovering effective drug combinations for diseases is challenging. DRACO, a new machine learning method, predicts synergistic drug pairs, significantly improving therapeutic discovery and reducing clinical trial costs.

More Related Videos

High-throughput Identification of Synergistic Drug Combinations by the Overlap2 Method

High-throughput Identification of Synergistic Drug Combinations by the Overlap² Method

Published on: May 21, 2018

A Data Integration Workflow to Identify Drug Combinations Targeting Synthetic Lethal Interactions

A Data Integration Workflow to Identify Drug Combinations Targeting Synthetic Lethal Interactions

Published on: May 27, 2021

Related Experiment Videos

Last Updated: Jun 20, 2026

A Knowledge Graph Approach to Elucidate the Role of Organellar Pathways in Disease via Biomedical Reports

A Knowledge Graph Approach to Elucidate the Role of Organellar Pathways in Disease via Biomedical Reports

Published on: October 13, 2023

High-throughput Identification of Synergistic Drug Combinations by the Overlap2 Method

High-throughput Identification of Synergistic Drug Combinations by the Overlap² Method

Published on: May 21, 2018

A Data Integration Workflow to Identify Drug Combinations Targeting Synthetic Lethal Interactions

A Data Integration Workflow to Identify Drug Combinations Targeting Synthetic Lethal Interactions

Published on: May 27, 2021

Area of Science:

Computational biology
Machine learning
Pharmacology

Background:

Developing novel drug combinations is crucial for treating complex diseases.
The vast number of potential drug pairs makes exhaustive clinical testing infeasible.
Existing methods lack the capacity to efficiently identify promising therapeutic combinations.

Purpose of the Study:

To introduce DRACO, a machine learning model for discovering effective therapeutic drug combinations.
To leverage a foundation model of drug biology and clinical trial data for prediction.
To identify optimal second drugs for combination therapy given a specific condition and drug.

Main Methods:

Developed DRACO, a machine learning approach integrating a drug biology foundation model.
Utilized a graph-based representation derived from clinical trial data.
Evaluated DRACO on predicting known drug combinations and distinguishing them from non-combinations.

Main Results:

DRACO successfully identified previously reported drug combinations with 80% accuracy.
The model achieved high performance in distinguishing true combinations from millions of candidates, ranking 99.0% of held-out combinations in the top 0.1%.
Demonstrated the model's capability to predict effective combination therapies for various disease phenotypes.

Conclusions:

DRACO offers a powerful computational tool for accelerating the discovery of novel drug combinations.
The method significantly enhances the efficiency of identifying synergistic drug therapies.
DRACO is expected to facilitate the development of new treatments across numerous diseases and drug candidates.